Nifty Healthcare Index Falls 1% as 18 Constituents Decline; Glenmark Defies Trend with 2.8% Gain
By Shishta Dutta | Published at: Jul 10, 2025 11:32 AM IST
Mumbai, July 10, 2025: The Nifty Healthcare Index experienced a notable decline, dropping 145.25 points or 1% to 14,389.65 as of 10:57 AM IST. This downturn reflected broad-based selling pressure across pharmaceutical and hospital stocks, with 18 out of 20 constituents trading in the red, signalling sectoral weakness driven by profit-booking and cautious investor sentiment.
Index Performance Snapshot (as of 11:15 AM)
| Metric | Value |
|---|---|
| Open | 14,506.75 |
| Day High | 14,518.80 |
| Day Low | 14,384.15 |
| Previous Close | 14,534.90 |
| Last Price | 14,389.65 |
| 1D Change | -145.25 |
| % Change | -1.00% |
| 52-Week High | 15,108.80 |
| 52-Week Low | 6,482.80 |
| 1-Year Return | 11.14% |
| 30-Day Return | 2.19% |
| Total Traded Value | ₹10,995.6 Cr |
| Total Traded Volume | 77.25 lakh shares |
Market Breadth (Nifty Healthcare Constituents)
| Advances | Declines | Unchanged |
|---|---|---|
| 2 | 18 | 0 |
Top Gainers
| Company | Last Price (₹) | Change (₹) | % Change | 52W High Proximity |
|---|---|---|---|---|
| Glenmark Pharmaceuticals | 1,869.80 | +51.00 | +2.80% | 0.51% from 52W H |
| Abbott India | 34,400.00 | +10.00 | +0.03% | 7.03% from 52W H |
Notable Losers
| Company | Last Price (₹) | Change (₹) | % Change |
|---|---|---|---|
| Cipla | 1,466.00 | -25.70 | -1.72% |
| Lupin | 1,882.20 | -32.00 | -1.67% |
| Fortis Healthcare | 772.60 | -12.10 | -1.54% |
| Zydus Lifesciences | 965.50 | -12.95 | -1.32% |
| Syngene International | 630.90 | -8.30 | -1.30% |
| Sun Pharma | 1,647.80 | -21.60 | -1.29% |
| Divi’s Laboratories | 6,894.00 | -89.50 | -1.28% |
Strategic Outlook
While the Nifty Healthcare Index has delivered a robust 11.14% return over the past year and a 2.19% gain in the last 30 days, it is currently facing selling pressure after nearing its 52-week high. The index trades just 4.76% below its record peak.
The market breadth, with only two advancing stocks, suggests that the current weakness is more indicative of selective profit-booking rather than a broad overbought condition across the entire sector. Heavyweights like Sun Pharmaceutical Industries Ltd., Divi’s Laboratories Ltd., and Cipla Ltd. hold significant weightage in the index (approximately 20.89%, 9.58%, and 6.26% respectively, as per recent data). Their individual performance can heavily influence the overall index movement.
What is the Nifty Healthcare Index?
The Nifty Healthcare Index is a thematic sectoral index on the National Stock Exchange (NSE) in India. Its primary purpose is to reflect the behaviour and performance of companies within the Indian healthcare sector. This includes a broad range of industries, such as:
- Pharmaceuticals
- Hospitals and healthcare service providers
- Diagnostics
- Biotechnology
- Medical equipment and supplies
- Healthcare research, analytics, and technology
- Pharmacy retail
The index comprises a maximum of 20 tradable, exchange-listed companies that meet specific eligibility criteria, primarily from the Nifty 500 universe. It is calculated using the free-float market capitalisation method, where the level of the index reflects the total free-float market value of all the stocks in the index relative to a particular base market capitalisation value. The index has a base date of April 1, 2005, and a base value of 1000.
What’s Ahead?
Investors will be closely watching upcoming sector-specific earnings reports, particularly from these large constituents, as they could potentially shift the current trend in the Nifty Healthcare Index. Factors like regulatory changes, government healthcare policies, R&D breakthroughs, and global demand for pharmaceuticals also continue to influence the sector’s performance.
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
